177 related articles for article (PubMed ID: 21393202)
1. Impetigo in a population over 8.5 years: incidence, fusidic acid resistance and molecular characteristics.
Rørtveit S; Skutlaberg DH; Langeland N; Rortveit G
J Antimicrob Chemother; 2011 Jun; 66(6):1360-4. PubMed ID: 21393202
[TBL] [Abstract][Full Text] [Related]
2. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France.
Laurent F; Tristan A; Croze M; Bes M; Meugnier H; Lina G; Vandenesch F; Etienne J
J Antimicrob Chemother; 2009 Feb; 63(2):420-1; author reply 421. PubMed ID: 18978362
[No Abstract] [Full Text] [Related]
3. Spread of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice patients in the south of The Netherlands.
Rijnders MI; Wolffs PF; Hopstaken RM; den Heyer M; Bruggeman CA; Stobberingh EE
J Antimicrob Chemother; 2012 May; 67(5):1176-80. PubMed ID: 22290345
[TBL] [Abstract][Full Text] [Related]
4. The decline of the impetigo epidemic caused by the epidemic European fusidic acid-resistant impetigo clone: an 11.5-year population-based incidence study from a community in Western Norway.
Rørtveit S; Skutlaberg DH; Langeland N; Rortveit G
Scand J Infect Dis; 2014 Dec; 46(12):832-7. PubMed ID: 25229166
[TBL] [Abstract][Full Text] [Related]
5. [An epidemic of bullous impetigo in the municipality of Austevoll in the year 2002].
Rørtveit S; Rørtveit G
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2557-60. PubMed ID: 14714041
[TBL] [Abstract][Full Text] [Related]
6. A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates.
O'Neill AJ; Larsen AR; Henriksen AS; Chopra I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3594-7. PubMed ID: 15328136
[TBL] [Abstract][Full Text] [Related]
7. Impetigo in epidemic and nonepidemic phases: an incidence study over 4(1/2) years in a general population.
Rørtveit S; Rortveit G
Br J Dermatol; 2007 Jul; 157(1):100-5. PubMed ID: 17553056
[TBL] [Abstract][Full Text] [Related]
8. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008).
Castanheira M; Watters AA; Mendes RE; Farrell DJ; Jones RN
J Antimicrob Chemother; 2010 Jul; 65(7):1353-8. PubMed ID: 20430787
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus.
O'Neill AJ; Larsen AR; Skov R; Henriksen AS; Chopra I
J Clin Microbiol; 2007 May; 45(5):1505-10. PubMed ID: 17344365
[TBL] [Abstract][Full Text] [Related]
10. A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway.
Tveten Y; Jenkins A; Kristiansen BE
J Antimicrob Chemother; 2002 Dec; 50(6):873-6. PubMed ID: 12461006
[TBL] [Abstract][Full Text] [Related]
11. Clonal spread among Swedish children of a Staphylococcus aureus strain resistant to fusidic acid.
Osterlund A; Eden T; Olsson-Liljequist B; Haeggman S; Kahlmeter G;
Scand J Infect Dis; 2002; 34(10):729-34. PubMed ID: 12477322
[TBL] [Abstract][Full Text] [Related]
12. Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.
Deplano A; Hallin M; Bustos Sierra N; Michel C; Prevost B; Martiny D; Yin N
J Antimicrob Chemother; 2023 Aug; 78(8):2061-2065. PubMed ID: 37358399
[TBL] [Abstract][Full Text] [Related]
13. Survey, characterization and susceptibility to fusidic acid of Staphylococcus aureus in the Carmarthen area.
El-Zimaity D; Kearns AM; Dawson SJ; Price S; Harrison GA
J Antimicrob Chemother; 2004 Aug; 54(2):441-6. PubMed ID: 15269197
[TBL] [Abstract][Full Text] [Related]
14. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis.
Alsterholm M; Flytström I; Bergbrant IM; Faergemann J
Acta Derm Venereol; 2010; 90(1):52-7. PubMed ID: 20107726
[TBL] [Abstract][Full Text] [Related]
15. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
Howden BP; Grayson ML
Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
[TBL] [Abstract][Full Text] [Related]
16. Characterization of fusidic acid-resistant Staphylococcus aureus isolates in the community of Casablanca (Morocco).
Elazhari M; Abu-Quatouseh LF; Elhabchi D; Zerouali K; Dersi N; Saile R; Timinouni M; Becker K
Int J Med Microbiol; 2012 Mar; 302(2):96-100. PubMed ID: 22197537
[TBL] [Abstract][Full Text] [Related]
17. Staphylococcus aureus resistant to fusidic acid among Swedish children: a follow-up study.
Osterlund A; Kahlmeter G; Haeggman S; Olsson-Liljequist B;
Scand J Infect Dis; 2006; 38(5):334-4. PubMed ID: 16724423
[TBL] [Abstract][Full Text] [Related]
18. Emergence and spread of a mupirocin-resistant variant of the European epidemic fusidic acid-resistant impetigo clone of
Yin N; Michel C; Makki N; Deplano A; Milis A; Prevost B; Miendje-Deyi VY; Hallin M; Martiny D
Euro Surveill; 2024 May; 29(19):. PubMed ID: 38726693
[TBL] [Abstract][Full Text] [Related]
19. Fusidic acid resistant Staphylococcus aureus and skin disease.
Lomholt HB
Acta Derm Venereol; 2010; 90(1):4. PubMed ID: 20107716
[No Abstract] [Full Text] [Related]
20. High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis.
McLaws F; Chopra I; O'Neill AJ
J Antimicrob Chemother; 2008 May; 61(5):1040-3. PubMed ID: 18299637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
